Results Of A First-Line Study Of Pembrolizumab In Advanced Urothelial Cancer

Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma

Targeted Oncology

Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Cancer | NEJM

LEAP-011: exploring first-line pembrolizumab + lenvatinib for advanced urothelial carcinoma

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study

European Society for Medical Oncology (ESMO)

First-line pembrolizumab combination fails to boost advanced urothelial cancer survival | Ajjai Alva

Medicine Matters oncology

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metast...

State of the Art lecture - Developments in metastatic urothelial cancer

European Association of Urology

PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab

Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma

Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer

Firstline pembrolizumab for metastatic urothelial cancer

IMvigor 210 Results in Metastatic Urothelial Carcinoma

Targeted Oncology

EV-302: 1L enfortumab vedotin in combination with pembrolizumab

Promising early results for cetrelimab plus erdafitinib reported for advanced UC | Thomas Powles

Medicine Matters oncology

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year fol...

First-line regorafenib 80mg/day with pembrolizumab in advanced HCC

Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer

Targeted Oncology

Impact of Age & Performance Status on Outcomes w First-Line Pembrolizumab for Urothelial Carcinoma